Lopez J J, Ho K K, Stoler R C, Caputo R P, Carrozza J P, Kuntz R E, Baim D S, Cohen D J
Charles A. Dana Research Institute, Boston, Massachusetts, USA.
J Am Coll Cardiol. 1997 Feb;29(2):345-52. doi: 10.1016/s0735-1097(96)00488-3.
We sought to evaluate the immediate angiographic results and intermediate-term follow-up after percutaneous treatment of left main coronary stenoses in the new device era.
Historically, balloon angioplasty of left main coronary stenoses has been associated with high procedural morbidity and poor long-term results. It is not clear whether new devices are more effective in this anatomic setting.
Between July 1993 and July 1995, we performed initial left main coronary interventions on 46 patients (mean age 67 +/- 12 years, 26% women). Quantitative angiography was available for 42 of 46 interventions, and clinical follow-up was obtained for all patients at 1 month, 6 months and 1 year after initial revascularization.
Most interventions (42 of 46) were performed in patients with "protected" coronary stenoses to the left coronary system owing to the presence of one or more patent left main coronary grafts. Seventy-seven percent of screened patients were deemed unsuitable for repeat coronary artery bypass surgery. Procedures performed included stenting in 73% of patients (alone in 30% and after rotational atherectomy in 43%), rotational atherectomy in 58% (alone in 15% and before stenting in 43%), directional atherectomy in 4% and angioplasty alone in 7%. Initial procedural success was achieved in all interventions, with no deaths, myocardial infarctions (creatine kinase, MB fraction > 50 IU/liter) or emergent bypass surgery. Follow-up data to date (median duration 9 months, range 6 to 19) demonstrate a 98% overall survival rate and a 6-month event-free survival rate of 78% (six target vessel revascularizations [TVRs], four non-TVRs).
Treatment of protected left main coronary artery stenoses can be accomplished safely and effectively with new device technology. Intermediate-term follow-up demonstrates an acceptably low rate of death, myocardial infarction or repeat revascularization at 6 months and 1 year.
我们试图评估在新器械时代经皮治疗左主干冠状动脉狭窄后的即时血管造影结果和中期随访情况。
从历史上看,左主干冠状动脉狭窄的球囊血管成形术一直与高手术并发症发生率和不良的长期结果相关。目前尚不清楚新器械在这种解剖情况下是否更有效。
在1993年7月至1995年7月期间,我们对46例患者(平均年龄67±12岁,女性占26%)进行了初次左主干冠状动脉介入治疗。46例介入治疗中有42例可进行定量血管造影,所有患者在初次血运重建后1个月、6个月和1年时进行了临床随访。
由于存在一根或多根通畅的左主干冠状动脉搭桥血管,大多数介入治疗(46例中的42例)是在左冠状动脉系统存在“受保护”冠状动脉狭窄的患者中进行的。77%的筛查患者被认为不适合再次进行冠状动脉搭桥手术。所进行的手术包括73%的患者接受支架置入术(30%单独进行,43%在旋磨术后进行),58%的患者接受旋磨术(15%单独进行,43%在支架置入术前进行),4%的患者接受定向旋切术,7%的患者仅接受血管成形术。所有介入治疗均取得了初始手术成功,无死亡、心肌梗死(肌酸激酶MB同工酶>50 IU/L)或急诊搭桥手术。迄今为止的随访数据(中位持续时间9个月,范围6至19个月)显示总生存率为98%,6个月无事件生存率为78%(6例靶血管血运重建[TVR],4例非TVR)。
采用新器械技术可安全有效地治疗受保护的左主干冠状动脉狭窄。中期随访显示,在6个月和1年时,死亡、心肌梗死或再次血运重建的发生率低至可接受水平。